SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

Completed · Phase 1

Conditions studied: Prostate Cancer

In brief

RATIONALE: SU5416 may stop the growth of cancer by stopping blood flow to the tumor. Androgens can stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, bicalutamide, leuprolide, or goserelin may fight prostate cancer by reducing the production of androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining SU5416, hormone therapy, and radiation therapy may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of SU5416 plus hormone therapy and radiation therapy in treating patients who have prostate cancer.

Key facts

Study ID

NCT00026377

Run by

University of Chicago

People needed

3

Starts

2001-11-01

Expected to finish

2003-04-01

Last updated by the study team

2013-09-05

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Radiation Oncology — Chicago, Illinois, United States
• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• LaGrange Memorial Hospital — LaGrange, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.